Screener
Bio-Rad Laboratories BIO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| (Provision for) benefit from income taxes | 162.7 | (19.4) |
| Net income (loss) | $(527.1) | $64.0 |
| Basic earnings (loss) per share: | ||
| Net income (loss) per basic share | $(19.55) | $2.29 |
| Weighted average common shares - basic | 26,958 | 27,941 |
| Diluted earnings (loss) per share: | ||
| Net income (loss) per diluted share | $(19.55) | $2.29 |
| Weighted average common shares - diluted | 26,958 | 27,955 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's EPS (diluted)?
- Bio-Rad Laboratories (BIO) reported EPS (diluted) of -$19.55 in Q1 2026.
- How has Bio-Rad Laboratories's EPS (diluted) changed year-over-year?
- Bio-Rad Laboratories's EPS (diluted) decreased by 953.7% year-over-year, from $2.29 to -$19.55.
- What is the long-term trend for Bio-Rad Laboratories's EPS (diluted)?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories's EPS (diluted) has grown at a -33.4% compound annual growth rate (CAGR), from $140.35 to $27.65.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Bio-Rad Laboratories's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude